IBD Relief


Soulage L’inconfort Du Côlon Irritable


$45.95 $36.76

En stock

Inflammatory bowel disorders (IBD) are characterized by cycles of chronic relapses and remissions, chronic inflammation of the intestinal mucosa and an abnormal gut micro-flora. Sufferers tend to be afflicted by symptoms of poor digestion including gas, bloating and abdominal pain. These disorders can involve food sensitivities to common allergens such as gluten, which is found in certain grains, and casein which is found in dairy products. Celiac Disease, a type of severe gluten intolerance, is believed to affect 1 in 200 people in the modernized world.  It causes an immune response to gluten which leads to intestinal inflammation and results in a decreased ability of the body to absorb nutrients.IBD Relief includes specialized digestive enzymes that help to prevent the intestinal inflammation related to food intolerances and chronic intestinal disorders. These include AN-peptidases which are a source of DPP-IV, which break down gluten and other problematic proteins. Anti-inflammatory and stress-relieving botanicals Boswellia serrata, ashwagandha, and ginger are also included in the formula, as well as vitamin D3 which is important for immune system regulation. The probiotic yeast Saccharomyces boulardii also helps to reduce inflammation in the gut and protect the bowel from pathogens by promoting healthy intestinal flora.Those who have inflammatory bowel disorders such as Crohn’s, Celiac Disease or colitis will benefit from taking IBD Relief. IBD Relief provides an innovative and effective combination of ingredients to help those with food sensitivities and intestinal inflammation to manage the symptoms and prevent exacerbation of the condition.
Serving Size: 4 Capsules
Ingrédients non médicinaux: Cellulose microcristalline, amidon de pomme de terre, maltodextrine de maïs, dextrine de tapioca et de pomme de terre, stéaryl fumarate de sodium et benzoate de sodium.
Boswellia Boswellia is well known for its anti-inflammatory effects. In clinical trials, promising results were obtained in UC patients using Boswellia. All parameters studied improved with boswellia supplementation, including stool properties, rectal biopsies, blood parameters, serum iron, calcium, proteins and eosinophils. Furthermore, 82% of the patients treated with boswellia went into remission whereas only 75% of the patients receiving sulfasalazine (an anti-inflammatory drug used to treat UC) experienced a remission. Similar results have also been shown for patients with Crohn’s disease. It is not surprising that according to the latest survey, 36% of German IBD patients surveyed use boswellia as part of their treatment protocol. Animal experiments have showed that boswellia modulates some components of the immune system, thereby reducing inflammation.Vitamin DVitamin D has been shown to inhibit the induction of auto-immune diseases such as systemic lupus erythematosus, type-1 diabetes and IBD. The vitamin D receptor also appears to have a critical role in the control and response of the colon to chemical injury as has been observed in studies using the development of animal models of human autoimmune diseases including experimental inflammatory bowel disease.GingerA study from the University of Michigan and funded by the National Cancer Institute found that taking ginger root supplements reduced intestinal inflammation by 28%. Ginger also has an excellent safety profile.Saccharomyces boulardiiS. boulardii is a probiotic yeast that is useful for fighting off disease-causing organisms in the intestinal tract. It is used for fighting inflammation and infection in the intestinal tract as a result of microbial imbalances. In an animal study, S. boulardiireduced the inflammation associated with irritable bowel syndrome (IBD), which suggests that Saccharomyces could play a role in reducing the symptoms of IBD. In a human study on ulcerative colitis, results indicated that it was is useful for fighting the inflammatory effects of the disease, and in some patients was even able to induce remission.AN PeptidesResearch has shown that prolyl endopeptidases (PEPs) can reduce the antigen toxicity of gluten, by cleaving proline-rich gluten peptides. PEP cleaves the gluten peptide into two shorter peptides that are cleaved further by brush-border enzymes at the intestinal microvilli. This reduces the vulnerability to gluten induced intestinal inflammation and reduces the immune response that leads to the inflammation of the lining of the gastrointestinal tract.DPP-IVPreliminary research has shown that DPP IV, one of the activities of AN-PEP, also cleaves and inactivates tumor necrosis factor alpha (TNF-α), regulating the extracellular TNF-α concentration. TNF-α is an immune messenger that promotes inflammation and plays a significant part in autoimmune disorders such as inflammatory bowel disease.
Please select a start rating
{{review.date | date:'medium'}}
Comment pending for approval
{{child.date | date:'medium'}}
Comment pending for approval
{{child2.date | date:'medium'}}
Comment pending for approval